A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

A groundbreaking approach led by a team of scientists, including Rice University chemist James Tour, has the potential to ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

What’s the reason for this? Your nasal cavity contains many blood vessels, which provide a more direct route for the drug into your bloodstream. When a drug is directly absorbed into your ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.